Pila Pharma, Malmö, Sweden.
Panum Institute, University of Copenhagen, Copenhagen, Denmark.
Trends Mol Med. 2017 Nov;23(11):1002-1013. doi: 10.1016/j.molmed.2017.09.005.
With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.
据估计，2016 年全球有 4.22 亿 2 型糖尿病（T2D）患者，该病已达到流行程度，是未满足的主要医疗需求之一。T2D 是一种具有慢性、低度炎症成分的多基因疾病。第二代瞬时受体电位香草酸 1（TRPV1）拮抗剂是具有临床安全性的有效抗炎药物。在 T2D 的啮齿动物模型中，TRPV1 阻断被证明可以阻止疾病进展并改善葡萄糖代谢。因此，我们认为 TRPV1 拮抗剂作为潜在的治疗 T2D 及其合并症的新治疗方法值得进一步研究。
